Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine

Overview

Journal Yonsei Med J

Specialty General Medicine

Date 2015 Aug 11

PMID 26256959

Citations 11

Authors

Hyun Seok Kim

Yeo-Jin Sung

Soonmyung Paik

Affiliations

Soon will be listed here.

Abstract

Since the first human cancer cell line, HeLa, was established in the early 1950s, there has been a steady increase in the number and tumor type of available cancer cell line models. Cancer cell lines have made significant contributions to the development of various chemotherapeutic agents. Recent advances in multi-omics technologies have facilitated detailed characterizations of the genomic, transcriptomic, proteomic, and epigenomic profiles of these cancer cell lines. An increasing number of studies employ the power of a cancer cell line panel to provide predictive biomarkers for targeted and cytotoxic agents, including those that are already used in clinical practice. Different types of statistical and machine learning algorithms have been developed to analyze the large-scale data sets that have been produced. However, much work remains to address the discrepancies in drug assay results from different platforms and the frequent failures to translate discoveries from cell line models to the clinic. Nevertheless, continuous expansion of cancer cell line panels should provide unprecedented opportunities to identify new candidate targeted therapies, particularly for the so-called "dark matter" group of cancers, for which pharmacologically tractable driver mutations have not been identified.

Citing Articles

Creation of an Isogenic H/N/KRAS-Less Mouse Embryonic Fibroblast Cell Line Panel Derived from a Size-Sorted Diploid Clone.

Burgan W, Fer N Methods Mol Biol. 2024; 2797:323-336.

PMID: 38570470 DOI: 10.1007/978-1-0716-3822-4_23.

HeLa cell segmentation using digital image processing.

Duque-Vazquez E, Sanchez-Yanez R, Saldana-Robles N, Leon-Galvan M, Cepeda-Negrete J Heliyon. 2024; 10(5):e26520.

PMID: 38434298 PMC: 10907640. DOI: 10.1016/j.heliyon.2024.e26520.

The challenge of making the right choice: patient avatars in the era of cancer immunotherapies.

Kayser C, Brauer A, Susanne S, Wandmacher A Front Immunol. 2023; 14:1237565.

PMID: 37638045 PMC: 10449253. DOI: 10.3389/fimmu.2023.1237565.

A Trans-Omics Comparison Reveals Common Gene Expression Strategies in Four Model Organisms and Exposes Similarities and Differences between Them.

Fores-Martos J, Forte A, Garcia-Martinez J, Perez-Ortin J Cells. 2021; 10(2).

PMID: 33562654 PMC: 7914595. DOI: 10.3390/cells10020334.

Improving the odds of success in antitumoral drug development using scoring approaches towards heterocyclic scaffolds.

Ion G, Olaru O, Nitulescu G, Olaru I, Tsatsakis A, Burykina T Oncol Rep. 2020; 44(2):589-598.

PMID: 32627025 PMC: 7336486. DOI: 10.3892/or.2020.7636.

References

Petrocca F, Altschuler G, Tan S, Mendillo M, Yan H, Jerry D . A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer Cell. 2013; 24(2):182-96. PMC: 3773329. DOI: 10.1016/j.ccr.2013.07.008. View

Garraway L, Lander E . Lessons from the cancer genome. Cell. 2013; 153(1):17-37. DOI: 10.1016/j.cell.2013.03.002. View

Singh N, Seo B, Vidyasagar M, White M, Kim H . siMacro: A Fast and Easy Data Processing Tool for Cell-Based Genomewide siRNA Screens. Genomics Inform. 2013; 11(1):55-7. PMC: 3630387. DOI: 10.5808/GI.2013.11.1.55. View

Dan S, Okamura M, Seki M, Yamazaki K, Sugita H, Okui M . Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations. Cancer Res. 2010; 70(12):4982-94. DOI: 10.1158/0008-5472.CAN-09-4172. View

Arumugam T, Ramachandran V, Fournier K, Wang H, Marquis L, Abbruzzese J . Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009; 69(14):5820-8. PMC: 4378690. DOI: 10.1158/0008-5472.CAN-08-2819. View

Hollestelle A, Nagel J, Smid M, Lam S, Elstrodt F, Wasielewski M . Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat. 2009; 121(1):53-64. DOI: 10.1007/s10549-009-0460-8. View

Ashraf S, Nicholls A, Wilding J, Ntouroupi T, Mortensen N, Bodmer W . Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. Proc Natl Acad Sci U S A. 2012; 109(51):21046-51. PMC: 3529069. DOI: 10.1073/pnas.1218750110. View

Yang W, Soares J, Greninger P, Edelman E, Lightfoot H, Forbes S . Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2012; 41(Database issue):D955-61. PMC: 3531057. DOI: 10.1093/nar/gks1111. View

Dangles-Marie V, Pocard M, Richon S, Weiswald L, Assayag F, Saulnier P . Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res. 2007; 67(1):398-407. DOI: 10.1158/0008-5472.CAN-06-0594. View

10.

Sadanandam A, Lyssiotis C, Homicsko K, Collisson E, Gibb W, Wullschleger S . A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013; 19(5):619-25. PMC: 3774607. DOI: 10.1038/nm.3175. View

11.

Schreiber S, Shamji A, Clemons P, Hon C, Koehler A, Munoz B . Towards patient-based cancer therapeutics. Nat Biotechnol. 2010; 28(9):904-6. PMC: 2939009. DOI: 10.1038/nbt0910-904. View

12.

Shoemaker R . The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006; 6(10):813-23. DOI: 10.1038/nrc1951. View

13.

Chen R, Belanger S, Frederick M, Li B, Johnston R, Xiao N . In vivo RNA interference screens identify regulators of antiviral CD4(+) and CD8(+) T cell differentiation. Immunity. 2014; 41(2):325-38. PMC: 4160313. DOI: 10.1016/j.immuni.2014.08.002. View

14.

Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D . Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012; 483(7387):100-3. DOI: 10.1038/nature10868. View

15.

Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, Haverty P . Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res. 2012; 22(12):2315-27. PMC: 3514662. DOI: 10.1101/gr.140988.112. View

16.

Kessler J, Kahle K, Sun T, Meerbrey K, Schlabach M, Schmitt E . A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2011; 335(6066):348-53. PMC: 4059214. DOI: 10.1126/science.1212728. View

17.

Gazdar A, Minna J . NCI series of cell lines: an historical perspective. J Cell Biochem Suppl. 1996; 24:1-11. DOI: 10.1002/jcb.240630502. View

18.

Shen L, Kondo Y, Ahmed S, Boumber Y, Konishi K, Guo Y . Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res. 2007; 67(23):11335-43. DOI: 10.1158/0008-5472.CAN-07-1502. View

19.

Kim H, Mendiratta S, Kim J, Pecot C, Larsen J, Zubovych I . Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell. 2013; 155(3):552-66. PMC: 3836195. DOI: 10.1016/j.cell.2013.09.041. View

20.

Masters J . HeLa cells 50 years on: the good, the bad and the ugly. Nat Rev Cancer. 2002; 2(4):315-9. DOI: 10.1038/nrc775. View